

Catalog# BP- 50569

## Galiximab Biosimilar (CD38 Monoclonal Antibody)

A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies.

Galiximab, an IgG (1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.

Product Details	
CAS No.	357613-77-5
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Galiximab Biosimilar
Conjugate	Unconjugated
Immunogen	Human CD80
Purity	>95%
Molecular Weight	145.24 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered solution, pH 6.0
Storage conditions	4°C for short time, -20°C or -80°C for long time.